

Center of Excellence 503B Product Reporting Compounded Products Update NDC Directory Office: CDER/OC/OCQC September 7, 2022



Learning Objectives

- Regulation
 - 503B Registration
 - 503B Product Reporting
- NDC Directory Search
- Summary
- Related Resources

Learning Objectives



FD&C Act



Upon Registration per 503B the Outsourcing Facility must:

- Submit an <u>initial product reporting</u> of all products compounded during the previous six-month period
- Submit product reports twice a year thereafter, in <u>June and</u>
 <u>December</u>



Compounded Products Online

- FDA received requests to:
 - Create a new marketing category
 - Include compounded drug NDCs in the NDC Directory
- FDA created marketing category:

"Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)"


 FDA published a new feature in the NDC Directory Search Search tool now includes "Compounded Products" (Outsourcing Facility Compounded Human Drug Products)

Compounded Products Online




• National Drug Code Directory & Outsourcing Facility Product Report

https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases



www.fda.gov

Compounded Products



NDC Directory & Product Reports

Compounded drug products

The NDC Directory also includes information about finished compounded human drug products produced by outsourcing facilities that have elected to assign NDCs to their products. Outsourcing facilities – a type of drug compounding facility regulated under Section 50;30 of the FD&C Act – can be eligible for exemptions from drug registration and listing requirements if they meet the conditions under Section 50;30. Outsourcing facilities may, but are not required to, assign NDCs to their finished compounded human drug products.

Outsourcing facilities are required to provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year. The NDC Directory draws data from these product reports.

The NDC Database only contains compounded drug products reported with the marketing category "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)" and that were assigned an NDC. Search results will include information reported to FDA within the last two years (last four reporting periods).*

*Inclusion of compounded drugs in the NDC Database coincides with the use of the marketing category "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)" beginning with the 2021-2 reporting period, i.e., June 0.1, 2021, thu November 30, 2021.

www.fda.gov

NDC Directory Search


- Daily Updates
- Select radio button for:

"Compounded Products"

• Notice green header

NDC Compounded products search

- Select Type
 - Nonproprietary name
 - NDC Code
 - Establishment information



FDA

NDC Directory Search: Example

EXAMPLE: search for product name the contains letters "fen"

• Select radio button for:

"Compounded Products"

• Notice green header

NDC Compounded products search

• Select Type from list:

"Nonproprietary Name"

 Enter at least three characters "fen"

FDA U.S. FOOD & DRUG	Follow FDA En Español		
ADMINISTRATION	Search FDA		
Home Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood &	Biologics Animal & Veterinary Cosmetics To	obacco Prod	
Home > Drug Databases > NDC			
National Drug Code Directory			
f share ♥ TWEET in LINKEDIN ♥ PINIT SE EMAIL ⊖ PRINT			
The National Drug Code (NDC) Directory is updated daily.			
Current through: 5/17/2022			
<u>NDC Application Programming Interface (API)</u> (Firefox and the second seco	Chrome recommended)		
○ Finished Products 0 ○ Unfinished Products 0	Compounded Products 0		
NDC Compounded products search			
Search the NDC database for Comp	ounded drug		
products			
Nonproprietary Name	~		
(ren			
Pageth Class			
Search Clear			
Background Information			
Drug questions email: DRUGINFO@FDA.HHS.GOV			
See also: Drug Registration and Listing Instructions			

www.fda.gov

NDC Directory Search: Result



PRODUCT NDC

- PRODUCT TYPE NAME
- NONPROPRIETARY NAME
- DOSAGE FORM NAME
- ROUTE (OF ADMIN.) NAME
- MARKETING CATEGORY NAME
- ESTABLISHMENT INFORMATION
- SUBSTANCE NAME
- ACTIVE INGREDIENTS INFORMATION
- NDC PACKAGE CODE
- PACKAGE DESCRIPTION
- REPORTING PERIOD
- DEA SCHEDULE

DA U.S. FOOD & DRUG					Follow FDA En Expand Search FDA							
		≡ Home	Food Drugs	Medical Devices	Radiation-Emitting Pro	oducts Vaccines, Blood	& Biologics Animal J	& Veterinary Cosm	atics Tobacco	Products		
Home > Drug	Databases > ND	0										
Nation	al Drug	Code Dire	ctory									
f share 🎐	TWEET in LINKED	IN 🚯 PIN IT 📓 EMAIL	PRINT									
Current throug	h May 23, 2022											
-		ounded drug produc	ts									
earch Results:		sanasa arag produc										
Back to Sea	rch Page Sea	arch Again										
CSV Ex												
	records per page								5	earch for text in the I	table:	
			DOSAGE		MARKETING			ACTIVE	NDC			
PRODUCT A	PRODUCT \$ TYPE NAME	NONPROPRIETARY \$	FORM \$	ROUTE NAME	CATEGORY \$	ESTABLISHMENT \$	SUBSTANCE \$	INGREDIENTS \$	PACKAGE \$	PACKAGE DESCRIPTION	REPORTING \$	DEA SCHED
	HUMAN	DICLOFENAC SODIUM DMSO 16/10	GEL	TOPICAL	OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG	Hybrid Pharma	DICLOFENAC SODIUM	160 mg/1 g	26436-5578-1	30 g in 1 JAR (26436-5578-1)	2021-2	
26436-5578	COMPOUNDED DRUG				PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)							
26436-5578 51754-9160		Fentanyi Citrate Injection 8000 mcg/100 mL	INJECTION	INTRAVENOUS	PRODUCT (EXEMPT FROM APPROVAL	Exela Pharma Sciences, LLC.	FENTANYL CITRATE	5000 ug/100 mL	51754-9180-1	100 mL in 1 VIAL, GLASS (51754- 9160-1)	2021-2	CII

OF Product Report: NDC

- The complete list is in the "product reports"
- Will include three years (last six reporting periods)
- The OF product report will include products with the new marketing category which became available on reporting period 2021-2.

Home / Dryca	/ Development & Approval Process Druca	/ Drug Approvals and Databases / National Drug Code Directory		
		National Drug Code	Directory	
	Drug Approvals and Databases Resources for Information Approved Drugs	Directorio de Códigos Nacionales de <u>Medicamentos</u> (Spanish Version) FDA's National Drug Code (XDC) Directory contains information about finished drug poducts, unfinished drugs and compounded drug poducts.	Deveload the New INC Express Mable Application	Content correct as of: 0510/0002 Regulated Product(s) Drugs
		Finished drug products Drug establishments are required to provide FDA with a current list of all drugs manifectured, propaged, propagated, compounded or processed for sale in the U.S. at their facilities. Drugs are identified and reported by the state of the theory of the state of the National Drug Code (XDC) which serves as the FDA's identifier (For GFDA) products the listed XDC mumbers in the <u>XDC Directory</u> which is updated daily.	Searching the NDC Directory is now faster and easier with our new mobile app! Download NDC Express	
		Compounded drug products The NDC Directory also includes information about finish products produced by outsourcing facilities that have elect products. Outsourcing facilities – a type of drug compount Section 5920 for HPBX-ALT – and be eligible for exampt listing requirements if they meet the conditions under see may, but are not required to assign NDCs to their finished	ed to assign NDCs to their ding facility regulated under ions from drug registration and tion 503B. Outsourcing facilities	

Outsourcing facilities are required to provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year. The NDC Directory draws data from these product reports



The NDC Database only contains compounded drug products reported with the marketing category "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)" and that were assigned an NDC. Search results will include information reported to FDA within the last two years (last four reporting periods). *

*Inclusion of compounded drugs in the NDC Database coincides with the use of the marketing category "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)" beginning with the 2021-2 reporting period, i.e., June 01, 2021, thru November 30, 2021.

OF Product Report: NDC cont..



- Complete outsourcing facility reports
- Must select a reporting year period
- Select type of search: Active Ingredients or Establishment Name
- Enter at least three characters
- Results
 - Active Ingredients
 - Active Ingredients Information
 - Dosage Form
 - Establishment Name
 - Package Description
 - NDC Package Code
 - Report Year Period

Outsourcing Facility Product Report

f SHARE	Y TWEET	in LINKEDIN	🔞 PIN IT	M EMAIL	
---------	---------	-------------	----------	---------	--

Outsourcing facilities are required to provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year. This database contains information reported to FDA within the last three years (last six reporting periods). This information may be used to identify outsourcing facilities that have produced certain drugs. This retrospective information does not identify drugs that outsourcing facilities intend to produce in the future.

earch the Outso atabase	ourcing Facility Produ	ct Report
Select Reporting Yea	r	
Select Type		
Enter at least three ch	aracters	

NDC compounded drugs file

- The complete list of compounded human drugs with an NDC as a file is available for download.
- File can be unzipped and read as an excel file.
- The file contains the following data elements:
 - PRODUCT NDC
 - PRODUCT TYPE NAME
 - PROPRIETARY NAME
 - PROPRIETARY NAME SUFFIX
 - NONPROPRIETARY NAME
 - DOSAGE FORM NAME
 - ROUTE [OF ADMINISTRATION] NAME
 - MARKETING CATEGORY NAME
 - LABELER NAME
 - SUBSTANCE NAME
 - ACTIVE INGREDIENTS INFO
 - DEA SCHEDULE
 - NDC PACKAGE CODE
 - PACKAGE DESCRIPTION
 - REPORTING PERIOD

For	For drug compounding, contact <u>Compounding@fda.hhs.gov</u> .								
Addi	tional References								
•	Search National Drug Code Directory								
•	<u>NDC database file - Text Version (zip format)</u>								
•	<u>NDC database file - Excel version (zip format)</u>								
<u>NDC unfinished drugs database file (zip format)</u>									
\sim	NDC compounded drugs database file (zip format)								
<u>NDC database excluded drugs database file (zip format)</u>									
<u>NDC product file definitions</u>									
<u>NDC package file definitions</u>									
•	NDC Application Programming Interface (Firefox and Chrome								
	recommended)								
FDA Archive	Visitor Information	FOIA							
About FDA	Website Policies / Privacy	HHS.gov							
<u>Accessibility</u>	<u>No FEAR Act</u>	<u>USA.gov</u>	^ Тор						

See points of contact for using registration and nating.

FD/

NDC Directory



Important Considerations

The NDC Directory contains compounded human drug products made by outsourcing facilities

- Assigned NDC within the last two years (last four reporting periods)
- Reported using the marketing category "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)"

- Publishing of the NDC does not constitute drug listing per FFDCA Section 510 and 21CFR207
- Assignment of an NDC number does not in any way denote FDA approval of the product
- Inclusion in the NDC Directory does not indicate that FDA has verified the information provided

Helpful Resources



- The Drug Quality and Security Act: Human Drug Compounding Outsourcing Facility: <u>https://www.fda.gov/drugs/human-drug-compounding/text-</u> <u>compounding-quality-act</u>
- Guidance for Industry: Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Final Guidance): <u>https://www.fda.gov/regulatory-information/search-fda-</u> guidance-documents/electronic-drug-product-reporting-human-drugcompounding-outsourcing-facilities-under-section-503b

Helpful Resources



• Drug Approvals and Databases:

https://www.fda.gov/drugs/development-approval-process-drugs/drugapprovals-and-databases

- Electronic Drug Registration and Listing Instructions: <u>https://www.fda.gov/drugs/drug-registration-and-listing-system-drls-and-</u> <u>edrls/electronic-drug-registration-and-listing-instructions</u>
- Human Drug Compounding Website: <u>https://www.fda.gov/drugs/guidance-compliance-regulatory-</u> <u>information/human-drug-compounding</u>

Helpful Resources

FDA

• National Drug Code Directory:

https://www.fda.gov/drugs/informationondrugs/ucm142438.htm

- NDC Directory Search: <u>https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm</u>
- Outsourcing Facility Product Report Search: <u>https://www.accessdata.fda.gov/scripts/cder/outsourcingfacility/index.cfm</u>
- NDC compounded drugs database file (zip format): <u>https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip</u>

Challenge Question

Which of the following are TRUE statements related to Outsourcing Facilities and Product Reporting?

- A. If available, the NDC for any source drug or bulk active ingredient must be reported to FDA.
- B. Assignment of an NDC number to a final product is not required.
- C. Only one search location is available for compounded human drugs with NDCs.
- D. If a firm registers in April 2021, they are not required to submit an initial product reporting as long as they submit one by end of June 2021.



Contact Us!



- eDRLS Helpdesk: edrls@fda.hhs.gov
- CDER Direct Helpdesk: <u>CDERdirect@fda.hhs.gov</u>
- Compounding Helpdesk: <u>Compounding@fda.hhs.gov</u>



